MeiraGTx Holdings plc (MGTX)

NMS – Цена в реальном времени. Валюта: USD

12.93

-0.12 (-0.92%)

Рынок открыт: Aug 12, 2026, 11:39 AM EDT

13.05

0.00 (0.00%)

Предыдущая сессия: Aug 11, 2026, 7:34 PM EDT

11.08.2026

Graviton BioScience Announces Clearance of Investigational New Drug (IND) for GV101 for the Treatment of Friedreich's Ataxia

Graviton received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for a novel capsule formulation of GV101 on August 7, 2026. FDA clearance marks a critical regulatory milestone in advancing this formulation of GV101, a capsule with improved PK and oral availability, into human trials for Friedreich's ataxia (FA).

06.08.2026

MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

LONDON and NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that the Compensation Committee of the Company's Board of Directors approved equity awards under the Company's 2026 Employment Inducement Award Plan to a new employee. The equity awards were granted as an inducement material to the new employee entering employment with MeiraGTx in accordance with Nasdaq Listing Rule 5635(c)(4).

Видео

No Data

There is no data to display

Пресс-релизы

11.08.2026

Graviton BioScience Announces Clearance of Investigational New Drug (IND) for GV101 for the Treatment of Friedreich's Ataxia

06.08.2026

MeiraGTx Holdings plc (MGTX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

MeiraGTx Holdings plc (MGTX)

Graviton BioScience Announces Clearance of Investigational New Drug (IND) for GV101 for the Treatment of Friedreich's Ataxia

MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Видео

No Data

Пресс-релизы

Graviton BioScience Announces Clearance of Investigational New Drug (IND) for GV101 for the Treatment of Friedreich's Ataxia

MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Graviton BioScience Announces Clearance of Investigational New Drug (IND) for GV101 for the Treatment of Friedreich's Ataxia

MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Видео

No Data

Пресс-релизы

Graviton BioScience Announces Clearance of Investigational New Drug (IND) for GV101 for the Treatment of Friedreich's Ataxia

MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Search stocks

MeiraGTx Holdings plc (MGTX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

MeiraGTx Holdings plc (MGTX)

Graviton BioScience Announces Clearance of Investigational New Drug (IND) for GV101 for the Treatment of Friedreich's Ataxia

MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Видео

No Data

Пресс-релизы

Graviton BioScience Announces Clearance of Investigational New Drug (IND) for GV101 for the Treatment of Friedreich's Ataxia

MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Graviton BioScience Announces Clearance of Investigational New Drug (IND) for GV101 for the Treatment of Friedreich's Ataxia

MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Видео

No Data

Пресс-релизы

Graviton BioScience Announces Clearance of Investigational New Drug (IND) for GV101 for the Treatment of Friedreich's Ataxia

MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)